Skip to main content

Roivant Sciences

Roivant Sciences Ltd. is a commercial-stage biopharmaceutical company that incubates, develops, and commercializes innovative medicines and healthcare technologies across diverse therapeutic areas. The company operates through a unique "Vant" model, founding nimble subsidiary companies focused on specific drug candidates, biological targets, and medical technologies in immunology, dermatology, and oncology. Its primary revenue drivers stem from commercial sales of approved pharmaceutical treatments, strategic out-licensing agreements, upfront milestone payments, and biopharmaceutical transaction proceeds. Roivant holds a prominent position in the biopharmaceutical industry as a pioneer in decentralized drug development, rapidly advancing late-stage clinical assets to regulatory approval. The enterprise focuses on executing global clinical trials, acquiring promising drug candidates from larger pharmaceutical firms, expanding its immunology pipeline, and developing targeted biological therapies. Roivant Sciences Ltd. maintains principal executive offices in New York, United States, and Basel, Switzerland, with its common stock publicly listed on the Nasdaq Global Select Market.

30 of the funds FundTelligence covers report a position in Roivant Sciences.

Legal name
Roivant Sciences Ltd
Sector
Health Care
Country
United States
Funds holding it
30
Exposure themes
Autoimmune diseases, Treatment, Women's Health

Funds holding Roivant Sciences

Showing the 8 largest of 30 funds holding it.

Loading...